AMENDMENTS TO THE CLAIMS

Please delete Claims 13-28 and substitute therefore Claims 29 - 54, as presented below. The status of all of the claims subsequent to entry of this Amendment will be as follows:

Claims 1-12 (cancelled)

Claims 13-28 (cancelled)

Claim 29 (new) A multi-dose ophthalmic composition comprising 0.01 to 2.0% w/v of a borate compound selected from the group consisting of boric acid, pharmaceutically acceptable salts of boric acid, and combinations thereof; 0.01 to 2.0% w/v of an amino alcohol having a molecular weight of 60 to 200 grams/mole; and water

Claim 30 (new) An ophthalmic composition according to Claim 29, wherein the composition further comprises 0.01 to 5.0% w/v of a polyol.

Claim 31 (new) An ophthalmic composition according to Claim 30 wherein the polyol comprises propylene glycol.

Claim 32 (new) An ophthalmic composition according to Claim 30, wherein the polyol is selected from the group consisting of mannitol, glycerin, xylitol, sorbitol, and combinations thereof.

Claim 33 (new) An ophthalmic composition according to Claim 32, wherein the polyol comprises sorbitol.

Claim 34 (new) An ophthalmic composition according to Claim 33, wherein the polyol further comprises propylene glycol.

Claim 35 (new) An ophthalmic composition according to Claim 30, wherein the borate concentration is 0.3 to 1.2% w/v and the polyol concentration is 0.6 to 2.0% w/v.

Claim 36 (new) An ophthalmic composition according to Claim 29, wherein the amino alcohol is selected from the group consisting of 2-amino-2-methyl-1-propanol (AMP), 2-dimethylamino-methyl-1-propanol (DMAMP), 2-amino-2-ethyl-1,3-propanediol (AEPD), 2-amino-2-methyl-1,3-propanediol (AMPD), 2-amino-1-butanol (AB), and combinations thereof.

Claim 37 (new) An ophthalmic composition according to Claim 36, wherein the amino alcohol comprises AMP.

Claim 38 (new) An ophthalmic composition according to Claim 37, wherein the composition further comprises 0.01 to 5.0% of a polyol.

Claim 39 (new) An ophthalmic composition according to Claim 38, wherein the borate concentration is 0.3 to 1.2% w/v and the polyol concentration is 0.6 to 2.0% w/v.

Claim 40 (new) An ophthalmic composition according to Claim 38, wherein the polyol comprises propylene glycol.

Claim 41 (new) An ophthalmic composition according to Claim 38, wherein the polyol is selected from the group consisting of mannitol, glycerin, xylitol, sorbitol, and combinations thereof.

Claim 42 (new) An ophthalmic composition according to Claim 41, wherein the polyol comprises sorbitol.

Claim 43 (new) An ophthalmic composition according to Claim 42, wherein the polyol further comprises propylene glycol.

Claim 44 (new) An ophthalmic composition according to Claim 29, wherein the composition does not contain a conventional anti-microbial preservative.

Claim 45 (new) An ophthalmic composition according to Claim 44, wherein the composition is adapted for use as an artificial tear.

Claim 46 (new) An ophthalmic composition according to Claim 44, wherein the composition is adapted for use as an ocular lubricant.

Claim 47 (new) An aqueous solution for disinfecting contact lenses, comprising:

0.01 to 2.0% w/v of an amino alcohol having a molecular weight of 60 to 200 grams/mole;

an antimicrobial agent in an amount effective to disinfect a contact lens;

a borate/polyol buffer system, said buffer system comprising a borate compound in an amount of 0.01 to 2.0% w/v and a polyol in an amount of 0.01 to 5.0% w/v; and

water

Claim 48 (new) An aqueous solution according to Claim 47, wherein the borate compound is selected from the group consisting of boric acid, pharmaceutically acceptable salts of boric acid, and combinations thereof; and the amino alcohol is selected from the group consisting of 2-amino-2-methyl-1-propanol (AMP), 2-dimethylamino-methyl-1-propanol (DMAMP), 2-amino-2-ethyl-1,3-propanediol (AEPD), 2-amino-2-methyl-1,3-propanediol (AMPD), 2-amino-1-butanol (AB), and combinations thereof.

Claim 49 (new) A solution according to Claim 48, wherein the amino alcohol comprises AMP.

Claim 50 (new) A sterile, multi-dose ophthalmic composition comprising 0.1 to 2.0% w/v of an amino alcohol having a molecular weight of 60 to 200 grams/mole; a borate/polyol buffer system, said buffer system comprising a borate compound in an amount of 0.01 to 2.0% w/v and a polyol in an amount of 0.01 to 5.0% w/v; and water, wherein said composition is adapted for use as an artificial tear or ocular lubricant and does not contain a conventional anti-microbial preservative.

Claim 51 (new) A composition according to Claim 50, wherein the borate compound is selected from the group consisting of boric acid, pharmaceutically acceptable salts of boric acid, and combinations thereof; and the amino alcohol is selected from the group consisting of 2-amino-2-methyl-1-propanol (AMP), 2-dimethylamino-methyl-1-propanol (DMAMP), 2-amino-2-ethyl-1,3-propanediol (AEPD), 2-amino-2-methyl-1,3-propanediol (AMPD), 2-amino-1-butanol (AB), and combinations thereof.

Claim 52 (new) A composition according to Claim 51, wherein the polyol comprises propylene glycol.

Claim 53 (new) A composition according to Claim 51, wherein the polyol is selected from the group consisting of mannitol, glycerin, xylitol, sorbitol, and combinations thereof.

Claim 54 (new) A composition according to Claim 53, wherein the amino alcohol comprises AMP.

Claim 55 (new) A composition according to Claim 53, wherein the polyol further comprises propylene glycol.

Claim 56 (new) A composition according to Claim 55, wherein the amino alcohol comprises AMP.

Claim 57 (new) A composition according to Claim 50, wherein the amino alcohol comprises AMP.